^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Soft Tissue Sarcoma
    Drug:Yondelis (trabectedin) (Alkylating agent, DNA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study.

    Published date:
    05/13/2020
    Excerpt:
    Selection criteria included patients with STS...High expression of CD274 (PD-L1) was significantly associated with better PFS of trabectedin (5.4 vs. 3.0 months; p= 0.006).
    DOI:
    10.1200/JCO.2020.38.15_suppl.11546